Vertex Pharmaceuticals is cutting about 20 positions in a functional reorganization at its Massachusetts operations. For a company with 10,000 employees, this is barely a rounding error. But Vertex's inclusion in 2026 layoff tracking matters because it shows that even highly profitable pharmaceutical companies with strong pipelines are trimming.
Vertex's primary franchise is in cystic fibrosis treatments, where it has near-monopoly pricing power. These cuts are organizational, not financial. The company is reshuffling teams rather than responding to business pressure.